Header Logo

Connection

Martin Maron to Aged

Back to Details
This is a "connection" page, showing publications Martin Maron has written about Aged.
Martin Maron
Connection Strength
1.886
Aged
  1. Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Kulac I, Lee MMY, Lewis GD, Ma CS, Michels M, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Olivotto I. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1821-1831.
    View in: PubMed
    Score: 0.079
  2. Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2024 May 21; 13(10):e033565.
    View in: PubMed
    Score: 0.077
  3. Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 05 30; 390(20):1849-1861.
    View in: PubMed
    Score: 0.077
  4. Maron MS, Mahmod M, Abd Samat AH, Choudhury L, Massera D, Phelan DMJ, Cresci S, Martinez MW, Masri A, Abraham TP, Adler E, Wever-Pinzon O, Nagueh SF, Lewis GD, Chamberlin P, Patel J, Yavari A, Dehbi HM, Sarwar R, Raman B, Valkovic L, Neubauer S, Udelson JE, Watkins H. Safety and Efficacy of Metabolic Modulation?With Ninerafaxstat in?Patients?With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 May 28; 83(21):2037-2048.
    View in: PubMed
    Score: 0.076
  5. Maron MS, Rastegar H, Dolan N, Carpino P, Koethe B, Maron BJ, Rowin EJ. Outcomes Over Follow-up =10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 01 15; 163:91-97.
    View in: PubMed
    Score: 0.065
  6. Rowin EJ, Maron BJ, Wells S, Burrows A, Firely C, Koethe B, Patel AR, Maron MS. Usefulness of Global Longitudinal Strain to Predict Heart Failure Progression in Patients With Nonobstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2021 07 15; 151:86-92.
    View in: PubMed
    Score: 0.063
  7. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, Maron MS. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2020 06 23; 75(24):3033-3043.
    View in: PubMed
    Score: 0.059
  8. Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 01 01; 125(1):120-126.
    View in: PubMed
    Score: 0.056
  9. Rowin EJ, Romashko M, Testani JM, Koethe BC, Saxena D, Udelson JE, Maron BJ, Maron MS. Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. J Card Fail. 2019 08; 25(8):690-692.
    View in: PubMed
    Score: 0.054
  10. Rowin EJ, Maron BJ, Chokshi A, Kannappan M, Arkun K, Wang W, Rastegar H, Maron MS. Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 10 15; 122(8):1409-1420.
    View in: PubMed
    Score: 0.051
  11. Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical Spectrum and Management?of?Heart Failure in?Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):353-363.
    View in: PubMed
    Score: 0.050
  12. Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of Exercise Testing in Hypertrophic?Cardiomyopathy. JACC Cardiovasc Imaging. 2017 11; 10(11):1374-1386.
    View in: PubMed
    Score: 0.049
  13. Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, Desnick RJ, Maron BJ. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 02; 131(2):200.e1-200.e8.
    View in: PubMed
    Score: 0.048
  14. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic Cardiomyopathy With Left?Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017 02 21; 69(7):761-773.
    View in: PubMed
    Score: 0.047
  15. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016 May 15; 117(10):1651-1654.
    View in: PubMed
    Score: 0.043
  16. Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
    View in: PubMed
    Score: 0.041
  17. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
    View in: PubMed
    Score: 0.041
  18. Chan RH, Maron BJ, Olivotto I, Assenza GE, Haas TS, Lesser JR, Gruner C, Crean AM, Rakowski H, Rowin E, Udelson J, Lombardi M, Tomberli B, Spirito P, Formisano F, Marra MP, Biagini E, Autore C, Manning WJ, Appelbaum E, Roberts WC, Basso C, Maron MS. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Aug 01; 116(3):436-41.
    View in: PubMed
    Score: 0.041
  19. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014 Aug 05; 130(6):484-95.
    View in: PubMed
    Score: 0.039
  20. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
    View in: PubMed
    Score: 0.035
  21. Shenoy C, Maron MS. Hypertrophic cardiomyopathy with left ventricular apical aneurysm in brothers. Am J Cardiol. 2011 Aug 15; 108(4):612-3.
    View in: PubMed
    Score: 0.031
  22. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011 Jul 05; 124(1):40-7.
    View in: PubMed
    Score: 0.031
  23. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009 Jul 14; 54(3):220-8.
    View in: PubMed
    Score: 0.027
  24. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008 Oct 07; 118(15):1541-9.
    View in: PubMed
    Score: 0.026
  25. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008 Apr 08; 51(14):1369-74.
    View in: PubMed
    Score: 0.025
  26. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, Maron BJ. Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy. Am J Cardiol. 2005 Jun 01; 95(11):1329-33.
    View in: PubMed
    Score: 0.021
  27. Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 May 01; 426:133082.
    View in: PubMed
    Score: 0.020
  28. Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.
    View in: PubMed
    Score: 0.020
  29. Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. 2024 Nov 08; 45(42):4464-4478.
    View in: PubMed
    Score: 0.020
  30. Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron MS, Nassif ME, Oreziak A, Owens AT, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh SF, Wang A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Sherrid MV, Abraham TP. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1839-1849.
    View in: PubMed
    Score: 0.020
  31. Tahir UA, Kolm P, Kwong RY, Desai MY, Dolman SF, Deng S, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Tiwari G, Friedrich MG, Zelaya-Portillo JH, Jerosch-Herold M, Kim DY, Maron MS, Piechnik SK, Schulz-Menger J, Watkins H, Weintraub WS, Neubauer S, Kramer CM, Jarolim P, Gerszten RE, Ho CY. Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy. Circ Heart Fail. 2024 Dec; 17(12):e011707.
    View in: PubMed
    Score: 0.020
  32. Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. JAMA Cardiol. 2024 Nov 01; 9(11):990-1000.
    View in: PubMed
    Score: 0.020
  33. Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, Solomon SD. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1789-1802.
    View in: PubMed
    Score: 0.020
  34. Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, Kulac IJ, Lee MMY, Maron MS, Merkely B, Michels M, Olivotto I, Oreziak A, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Solomon SD, Wohltman A, Kwong RY, Kramer CM. Effect of Aficamten on Cardiac Structure?and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1806-1817.
    View in: PubMed
    Score: 0.020
  35. Sherrod CF, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA. Effect of Aficamten on Health Status?Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1773-1785.
    View in: PubMed
    Score: 0.020
  36. Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc. 2024 Aug 06; 13(15):e035993.
    View in: PubMed
    Score: 0.019
  37. Aglan A, Fath AR, Maron BJ, Maron MS, Prasad A, Almomani A, Hammadah M, Reynolds MR, Rowin EJ. Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024 09; 21(9):1677-1683.
    View in: PubMed
    Score: 0.019
  38. Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail. 2024 Nov; 30(11):1439-1448.
    View in: PubMed
    Score: 0.019
  39. Butzner M, Maron MS, Sarocco P, Teng CC, Stanek E, Tan H, Robertson LA. Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy. J Invasive Cardiol. 2022 12; 34(12):E866-E872.
    View in: PubMed
    Score: 0.017
  40. Butzner M, Sarocco P, Maron MS, Rowin E, Teng CC, Stanek E, Tan H, Robertson LA. Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. Am J Cardiol. 2022 07 01; 174:120-125.
    View in: PubMed
    Score: 0.017
  41. Kramer CM, DiMarco JP, Kolm P, Ho CY, Desai MY, Kwong RY, Dolman SF, Desvigne-Nickens P, Geller N, Kim DY, Maron MS, Appelbaum E, Jerosch-Herold M, Friedrich MG, Schulz-Menger J, Piechnik SK, Mahmod M, Jacoby D, White J, Chiribiri A, Helms A, Choudhury L, Michels M, Bradlow W, Salerno M, Dawson DK, Weinsaft JW, Berry C, Nagueh SF, Buccarelli-Ducci C, Owens A, Casadei B, Watkins H, Weintraub WS, Neubauer S. Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR. JACC Clin Electrophysiol. 2021 11; 7(11):1376-1386.
    View in: PubMed
    Score: 0.016
  42. Larson A, Libermann TA, Bowditch H, Das G, Diakos N, Huggins GS, Rastegar H, Chen FY, Rowin EJ, Maron MS, Chin MT. Plasma Proteomic Profiling in Hypertrophic Cardiomyopathy Patients before and after Surgical Myectomy Reveals Post-Procedural Reduction in Systemic Inflammation. Int J Mol Sci. 2021 Mar 01; 22(5).
    View in: PubMed
    Score: 0.015
  43. Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
    View in: PubMed
    Score: 0.015
  44. Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
    View in: PubMed
    Score: 0.015
  45. Sherrid MV, Riedy K, Rosenzweig B, Massera D, Saric M, Swistel DG, Ahluwalia M, Arabadjian M, DeFonte M, Stepanovic A, Serrato S, Xia Y, Zhong H, Maron MS, Maron BJ, Reynolds HR. Distinctive Hypertrophic Cardiomyopathy Anatomy and Obstructive Physiology in Patients Admitted With Takotsubo Syndrome. Am J Cardiol. 2020 06 01; 125(11):1700-1709.
    View in: PubMed
    Score: 0.014
  46. Rowin EJ, Maron MS, Bhatt V, Gillam L, Maron BJ. Hypertrophic Cardiomyopathy in "Real-World" Community Cardiology Practice. Am J Cardiol. 2020 05 01; 125(9):1398-1403.
    View in: PubMed
    Score: 0.014
  47. Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Friedrich MG, Geller N, Harper AR, Jarolim P, Jerosch-Herold M, Kim DY, Maron MS, Schulz-Menger J, Piechnik SK, Thomson K, Zhang C, Watkins H, Weintraub WS, Kramer CM. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019 11 12; 74(19):2333-2345.
    View in: PubMed
    Score: 0.014
  48. Fahmy AS, Neisius U, Chan RH, Rowin EJ, Manning WJ, Maron MS, Nezafat R. Three-dimensional Deep Convolutional Neural Networks for Automated Myocardial Scar Quantification in Hypertrophic Cardiomyopathy: A Multicenter Multivendor Study. Radiology. 2020 01; 294(1):52-60.
    View in: PubMed
    Score: 0.014
  49. Sharkey SW, Kalra A, Henry TD, Smith TD, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Coexistence of acute takotsubo syndrome and acute coronary syndrome. Catheter Cardiovasc Interv. 2020 10 01; 96(4):825-829.
    View in: PubMed
    Score: 0.014
  50. Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ. Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2019 11 05; 8(21):e012041.
    View in: PubMed
    Score: 0.014
  51. Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, Rastegar H, Kapur NK, Weintraub AR, Maron BJ, Maron MS, Rowin EJ. Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. Circ Cardiovasc Interv. 2019 07; 12(7):e007673.
    View in: PubMed
    Score: 0.014
  52. Miller CAS, Maron MS, Estes NAM, Price LL, Rowin EJ, Maron BJ, Link MS. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 06 01; 123(11):1859-1862.
    View in: PubMed
    Score: 0.013
  53. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
    View in: PubMed
    Score: 0.013
  54. Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017 Dec 19; 136(25):2420-2436.
    View in: PubMed
    Score: 0.012
  55. Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR, Maron BJ, Maron MS, Maron BA. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. Circ Heart Fail. 2017 Apr; 10(4):e003689.
    View in: PubMed
    Score: 0.012
  56. Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 06 01; 119(11):1862-1865.
    View in: PubMed
    Score: 0.012
  57. Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
    View in: PubMed
    Score: 0.012
  58. Williams LK, Chan RH, Carasso S, Durand M, Misurka J, Crean AM, Ralph-Edwards A, Gruner C, Woo A, Lesser JR, Maron BJ, Maron MS, Rakowski H. Effect of Left Ventricular Outflow Tract Obstruction on Left Atrial Mechanics in Hypertrophic Cardiomyopathy. Biomed Res Int. 2015; 2015:481245.
    View in: PubMed
    Score: 0.011
  59. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, Ralph-Edwards A, Rakowski H, Sherrid MV, Swistel DG, Balaram S, Rastegar H, Rowin EJ, Smedira NG, Lytle BW, Desai MY, Lever HM. Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. J Am Coll Cardiol. 2015 Sep 15; 66(11):1307-1308.
    View in: PubMed
    Score: 0.011
  60. Sharkey SW, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):765-72.
    View in: PubMed
    Score: 0.010
  61. Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, DiMarco JP, Friedrich MG, Geller N, Heckler S, Ho CY, Jerosch-Herold M, Ivey EA, Keleti J, Kim DY, Kolm P, Kwong RY, Maron MS, Schulz-Menger J, Piechnik S, Watkins H, Weintraub WS, Wu P, Neubauer S. Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015 Aug; 170(2):223-30.
    View in: PubMed
    Score: 0.010
  62. Biagini E, Olivotto I, Iascone M, Parodi MI, Girolami F, Frisso G, Autore C, Limongelli G, Cecconi M, Maron BJ, Maron MS, Rosmini S, Formisano F, Musumeci B, Cecchi F, Iacovoni A, Haas TS, Bacchi Reggiani ML, Ferrazzi P, Salvatore F, Spirito P, Rapezzi C. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am J Cardiol. 2014 Sep 01; 114(5):769-76.
    View in: PubMed
    Score: 0.010
  63. Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm. 2013 Feb; 10(2):214-8.
    View in: PubMed
    Score: 0.009
  64. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm. 2012 Jan; 9(1):57-63.
    View in: PubMed
    Score: 0.008
  65. Maron BJ, Maron MS, Maron BA, Haas TS, Altman RK, Smalley SJ, Doerer JJ, Link MS, Mooney MR. Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011 Jun 14; 57(24):2454-6.
    View in: PubMed
    Score: 0.008
  66. Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26; 55(4):333-41.
    View in: PubMed
    Score: 0.007
  67. Spirito P, Autore C, Rapezzi C, Bernab? P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barill? CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009 Apr 07; 119(13):1703-10.
    View in: PubMed
    Score: 0.007
  68. Sharkey SW, Maron BJ, Nelson P, Parpart M, Maron MS, Bristow MR. Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol. 2009 Feb; 53(1):53-7.
    View in: PubMed
    Score: 0.007
  69. Sharkey SW, Lesser JR, Menon M, Parpart M, Maron MS, Maron BJ. Spectrum and significance of electrocardiographic patterns, troponin levels, and thrombolysis in myocardial infarction frame count in patients with stress (tako-tsubo) cardiomyopathy and comparison to those in patients with ST-elevation anterior wall myocardial infarction. Am J Cardiol. 2008 Jun 15; 101(12):1723-8.
    View in: PubMed
    Score: 0.006
  70. Dinwoodey DL, Skinner M, Maron MS, Davidoff R, Ruberg FL. Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy. Am J Cardiol. 2008 Mar 01; 101(5):674-6.
    View in: PubMed
    Score: 0.006
  71. Maddukuri PV, Vieira ML, DeCastro S, Maron MS, Kuvin JT, Patel AR, Pandian NG. What is the best approach for the assessment of left atrial size? Comparison of various unidimensional and two-dimensional parameters with three-dimensional echocardiographically determined left atrial volume. J Am Soc Echocardiogr. 2006 Aug; 19(8):1026-32.
    View in: PubMed
    Score: 0.006
  72. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005 Aug 02; 46(3):470-6.
    View in: PubMed
    Score: 0.005
  73. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005 Aug 02; 46(3):480-7.
    View in: PubMed
    Score: 0.005
  74. Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, Maron BJ. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005 Feb 01; 111(4):472-9.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.